The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 560-565

  Dawson, N A ^a,b   McLeod, D G ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

APPETITE; CANCER HORMONE THERAPY; CANCER PAIN; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; QUALITY OF LIFE; REVIEW;

EID: 0030969232     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00443-1     Document Type: Article

References (46)

1. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43, 209-223.
2. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936, 28, 485-495.
3. Blackard CE. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Chemother Rep 1975, 59, 225-227.
4. Scott WW, Gibbons RP, Johnson DE, et al. Comparison of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC 26271) in patients with advanced carcinoma of the prostate. Cancer Chemother Rep 1975, 59, 195-201.
5. Slack NH, Murphy GP, and Participants in the National Prostate Cancer Project. Criteria for evaluating patient responses to treatment modalities for prostate cancer. Urol Clin N Am 1984, 11, 337-342.
6. Murphy GP, Beckley S, Brady MF, et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983, 51, 1264-1272.
7. Smith PH, Bono A, da Silva C, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer 1990, 66, 1009-1016.
8. Lund F, Smith PH, Suciu S and the EORTC Urological Group. Do bone scans predict prognosis in prostatic cancer? A report of the EORTC protocol 30762. Br J Urol 1984, 56, 58-63.
9. Pollen JJ, Gerber K, Ashburn WL, et al. Nuclear bone imaging in metastatic cancer of the prostate. Cancer 1981, 47, 2585-2594.
10. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionucleotide bone scan in metastatic prostate cancer. Am J Roentgenol 1984, 142, 773-776.
11. Citrin DL, Tuohy JB, Bessent RG, et al. Quantitative bone scanning: a method for assessing responses of bone metastases to treatment. Lancet 1974, 1, 1132-1133.
12. Drelichman A, Decker DA, Al-Sarraf M, et al. Computerized bone scan. Cancer 1984, 53, 1061-1065.
13. Sabbatini P, Yeung H, Imbriaco M, et al. The correlation of serial bone scintigraphy and PSA determinations in patients (pts) with androgen independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 1996, 15, 254 (abstract).
14. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990, 66, 1017-1021.
15. Fitzpatrick JM, Constable AR, Sherwood T, et al. Serial bone scanning: the assessment of treatment response in carcinoma of the prostate. Br J Urol 1978, 50, 555-561.
16. Newling DWW, Denis L, Vermeylen K, for the European Organization for Research and Treatment of Cancer-Genituorinary Group. Orchiectomy versus goserelin and nutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 1993, 72, 3793-3798.
17. Ercole CJ, Lange PH, Mathisen M, et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987, 138, 1181-1184.
18. Daver A, Soret JY, Coblentz Y, et al. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol 1988, 11, S53-S60.
19. Ahmann FR, Marx P, Ahmann M. Predicting response to therapy in metastatic prostate cancer with serum prostate specific antigen (PSA) levels. Proc Am Soc Clin Oncol 1990, 9, 134 (abstract).
20. Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (zoladex). Br J Urol 1986, 58, 676-682.
21. Cooper EH, Armitage TG, Robinson MRG, et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990, 66, 1025-1028.
22. Smith JA, Crawford ED, Lange PH, et al. PSA correlation with response and survival in advanced carcinoma of the prostate. J Urol 1993, 149, 430A.
23. Miller JI, Ahmann FR, Drach GW, et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992, 147, 956-961.
24. Arai Y, Yoshiki T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990, 144, 1415-1419.
25. Matzkin H, Eber P, Todd B, et al. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992, 70, 2302-2309.
26. Eisenberger M, Crawford ED, McLeod DG, et al. The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105. Proc Am Soc Clin Oncol 1995, 14, 235 (abstract).
27. Kelly WK, Scher HI, Mazumdar M, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993, 11, 607-615.
28. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995, 13, 2944-2953.
29. Kelly WK, Steineck G, Mazumdar M, et al. Post-therapy changes in biochemical markers in patients with androgen independent prostate cancer. Proc Am Soc Clin Oncol 1995, 14, 233 (abstract).
30. Cassileth BR. Patients' attitudes and quality of life in late-stage prostate cancer. In Wein AJ, Malkowicz SB, eds. Controversies in the Management of Prostate Cancer, Part 6, Late Stage Prostatic Cancer: Quality of Life Issues and Patient Attitudes. Pennsylvania, CoMed Communications, 1991.
31. World Health Organization. The first ten years of the World Health Organization, Geneva. The World Health Organization, 1958.
32. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In McLeod CM, ed. Evolution of Chemotherapeutic Agents in Cancer. New York, Columbia University Press, 1949, 102-105.
33. Schipper H, Levitt M. Measuring quality of life: risks and benefits. Cancer Treat Rep 1985, 69, 1115-1123.
34. Ganz PA, Schag CAC, Lee JJ, et al. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res 1992, 1, 19-29.
35. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients. The Functional Living Index - Cancer: development and validation. J Clin Oncol 1984, 2, 472-483.
36. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993, 11, 570-579.
37. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. J Chron Dis 1981, 34, 585-597.
38. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-life assessment in clinical trials. Rec Res Cancer Res 1988, 111, 231-249.
39. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988, 26, 724.
40. Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976, 1, 899-901.
41. Peeling WB. Phase III studies to compare goserelin with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989, 33, 45-52.
42. Herr H, Kornblith A, Ofman U. A comparison of the quality of life in patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993, 71(Suppl.), 1143-1150.
43. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1992, 1, 323-329.
44. Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995, 45, 839-845.
45. Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996, 14, 1756-1764.
46. Crawford ED, Stone NN, Garnick M, et al. Results of a national survey of urology practice patterns and patient experience from men with prostate cancer. J Urol 1996, 155, 606A.